IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
IRADIMED (NASDAQ: IRMD) has scheduled its first quarter 2025 financial results announcement for Friday, May 5, 2025, before market opening. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results and address questions.
Interested participants can register for the conference call through a provided link, after which they will receive dial-in details and a unique pin. The call will also be available via live webcast on the company's investor relations website, with a recording accessible afterward.
IRADIMED (NASDAQ: IRMD) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per venerdì 5 maggio 2025, prima dell'apertura dei mercati. La società terrà una conference call alle 9:00 a.m. ora Eastern dello stesso giorno per discutere i risultati e rispondere alle domande.
Gli interessati possono registrarsi alla conference call tramite un link fornito, dopo di che riceveranno i dettagli per la chiamata e un PIN univoco. La chiamata sarà inoltre disponibile in diretta streaming sul sito web delle relazioni con gli investitori della società, con una registrazione accessibile successivamente.
IRADIMED (NASDAQ: IRMD) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el viernes 5 de mayo de 2025, antes de la apertura del mercado. La compañía llevará a cabo una conferencia telefónica a las 9:00 a.m. hora del Este ese mismo día para discutir los resultados y responder preguntas.
Los interesados pueden registrarse para la conferencia telefónica a través de un enlace proporcionado, tras lo cual recibirán los detalles de acceso y un PIN único. La llamada también estará disponible en webcast en vivo en el sitio web de relaciones con inversionistas de la empresa, con una grabación accesible posteriormente.
IRADIMED (NASDAQ: IRMD)는 2025년 1분기 재무 결과를 2025년 5월 5일 금요일 시장 개장 전 발표할 예정입니다. 회사는 같은 날 동부 표준시 오전 9시에 결과를 논의하고 질문에 답변하기 위한 컨퍼런스 콜을 진행합니다.
참가를 원하는 분들은 제공된 링크를 통해 컨퍼런스 콜에 등록할 수 있으며, 등록 후 전화 접속 정보와 고유 PIN을 받게 됩니다. 또한 이 콜은 회사 투자자 관계 웹사이트에서 라이브 웹캐스트로도 시청 가능하며, 이후 녹화본도 제공됩니다.
IRADIMED (NASDAQ : IRMD) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le vendredi 5 mai 2025, avant l'ouverture des marchés. La société tiendra une conférence téléphonique à 9h00, heure de l'Est le même jour pour discuter des résultats et répondre aux questions.
Les participants intéressés peuvent s'inscrire à la conférence téléphonique via un lien fourni, après quoi ils recevront les informations d'accès et un code PIN unique. L'appel sera également disponible en webcast en direct sur le site des relations investisseurs de la société, avec un enregistrement accessible par la suite.
IRADIMED (NASDAQ: IRMD) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Freitag, den 5. Mai 2025, vor Börsenöffnung, geplant. Das Unternehmen wird am selben Tag um 9:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Fragen zu beantworten.
Interessierte Teilnehmer können sich über einen bereitgestellten Link für die Telefonkonferenz registrieren, woraufhin sie Einwahldaten und eine individuelle PIN erhalten. Die Konferenz wird auch als Live-Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer anschließenden Aufzeichnung.
- None.
- None.
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adff
Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
Please visit www.iradimed.com for more information.
Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
When will IRMD release its Q1 2025 earnings report?
How can investors join IRMD's Q1 2025 earnings call?
What time is IRADIMED's Q1 2025 earnings conference call?
Will IRMD's Q1 2025 earnings call be available for replay?
